High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review. Issue 24 (June 2018)

• Record Type: Journal Article
• Authors: Xia, Dandan; Wang, Huiyu; Wang, Runjie; Liu, Chaoying; Xu, Junying
• Other Names: NA. section editor.
• Is Part Of: Medicine. Volume 97:Issue 24(2018)
• Publication Date: 2018-06
• Subjects: breast cancer -- endocrine therapy -- fulvestrant -- renal metastasis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000011115
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. Patient concerns: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure. Diagnoses: The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2). Interventions: The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month. Outcomes: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved. Lessons: Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2− advanced breast cancer with renal metastasis after SERMs failure.